TY - JOUR
T1 - Development of a multiomics database for personalized prognostic forecasting in head and neck cancer
T2 - The Big Data to Decide EU Project
AU - Cavalieri, Stefano
AU - De Cecco, Loris
AU - Brakenhoff, Ruud H.
AU - Serafini, Mara Serena
AU - Canevari, Silvana
AU - Rossi, Silvia
AU - Lanfranco, Davide
AU - Hoebers, Frank J. P.
AU - Wesseling, Frederik W. R.
AU - Keek, Simon
AU - Scheckenbach, Kathrin
AU - Mattavelli, Davide
AU - Hoffmann, Thomas
AU - Lopez Perez, Laura
AU - Fico, Giuseppe
AU - Bologna, Marco
AU - Nauta, Irene
AU - Leemans, C. Rene
AU - Trama, Annalisa
AU - Klausch, Thomas
AU - Berkhof, Johannes Hans
AU - Tountopoulos, Vasilis
AU - Shefi, Ron
AU - Mainardi, Luca
AU - Mercalli, Franco
AU - Poli, Tito
AU - Licitra, Lisa
AU - BD2Decide Consortium
N1 - Funding Information:
The authors and the investigators are grateful to Dr. Elena Martinelli, project manager of the BD2Decide project, who lead the Coordination work. Editorial assistance and English language editing (funded by the BD2Decide Consortium) were provided by Charlesworth Author Service.
Publisher Copyright:
© 2020 The Authors. Head & Neck published by Wiley Periodicals LLC.
PY - 2021/2
Y1 - 2021/2
N2 - Background Despite advances in treatments, 30% to 50% of stage III-IV head and neck squamous cell carcinoma (HNSCC) patients relapse within 2 years after treatment. The Big Data to Decide (BD2Decide) project aimed to build a database for prognostic prediction modeling.Methods Stage III-IV HNSCC patients with locoregionally advanced HNSCC treated with curative intent (1537) were included. Whole transcriptomics and radiomics analyses were performed using pretreatment tumor samples and computed tomography/magnetic resonance imaging scans, respectively.Results The entire cohort was composed of 71% male (1097)and 29% female (440): oral cavity (429, 28%), oropharynx (624, 41%), larynx (314, 20%), and hypopharynx (170, 11%); median follow-up 50.5 months. Transcriptomics and imaging data were available for 1284 (83%) and 1239 (80%) cases, respectively; 1047 (68%) patients shared both.Conclusions This annotated database represents the HNSCC largest available repository and will enable to develop/validate a decision support system integrating multiscale data to explore through classical and machine learning models their prognostic role.
AB - Background Despite advances in treatments, 30% to 50% of stage III-IV head and neck squamous cell carcinoma (HNSCC) patients relapse within 2 years after treatment. The Big Data to Decide (BD2Decide) project aimed to build a database for prognostic prediction modeling.Methods Stage III-IV HNSCC patients with locoregionally advanced HNSCC treated with curative intent (1537) were included. Whole transcriptomics and radiomics analyses were performed using pretreatment tumor samples and computed tomography/magnetic resonance imaging scans, respectively.Results The entire cohort was composed of 71% male (1097)and 29% female (440): oral cavity (429, 28%), oropharynx (624, 41%), larynx (314, 20%), and hypopharynx (170, 11%); median follow-up 50.5 months. Transcriptomics and imaging data were available for 1284 (83%) and 1239 (80%) cases, respectively; 1047 (68%) patients shared both.Conclusions This annotated database represents the HNSCC largest available repository and will enable to develop/validate a decision support system integrating multiscale data to explore through classical and machine learning models their prognostic role.
KW - big data
KW - head and neck cancer
KW - prognostic models
KW - radiomics
KW - transcriptomics
KW - QUALITY-OF-LIFE
KW - HUMAN-PAPILLOMAVIRUS
KW - EUROPEAN-ORGANIZATION
KW - OROPHARYNGEAL CANCER
KW - CARCINOMA PATIENTS
KW - SURVIVAL
KW - VALIDATION
KW - COMORBIDITY
KW - PREDICTION
KW - SIGNATURE
U2 - 10.1002/hed.26515
DO - 10.1002/hed.26515
M3 - Article
C2 - 33107152
SN - 1043-3074
VL - 43
SP - 601
EP - 612
JO - Head and Neck-Journal for the Sciences and Specialties of the Head and Neck
JF - Head and Neck-Journal for the Sciences and Specialties of the Head and Neck
IS - 2
ER -